Jeannette JD - Uniqure NV Chief Secretary
| QURE Stock | USD 5.99 0.21 3.63% |
Executive
Jeannette JD is Chief Secretary of Uniqure NV
| Age | 62 |
| Address | Paasheuvelweg 25, Amsterdam, Netherlands, 1105 BP |
| Phone | 31 20 240 6000 |
| Web | https://www.uniqure.com |
Uniqure NV Management Efficiency
The company has return on total asset (ROA) of (0.1662) % which means that it has lost $0.1662 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.4757) %, meaning that it created substantial loss on money invested by shareholders. Uniqure NV's management efficiency ratios could be used to measure how well Uniqure NV manages its routine affairs as well as how well it operates its assets and liabilities. As of November 26, 2024, Return On Tangible Assets is expected to decline to -0.43. In addition to that, Return On Capital Employed is expected to decline to -0.39. At present, Uniqure NV's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 18.6 M, whereas Return On Tangible Assets are forecasted to decline to (0.43).Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Yingli Ma | Structure Therapeutics American | 50 | |
| Fang Zhang | Structure Therapeutics American | N/A | |
| Steve Sabus | Syndax Pharmaceuticals | 57 | |
| Gregory Perry | Merus BV | 64 | |
| Shabbir Anik | Sutro Biopharma | 71 | |
| III JD | Avidity Biosciences | 66 | |
| Ashley PharmD | Merus BV | N/A | |
| Ross Moat | Kiniksa Pharmaceuticals | 43 | |
| Carsten Boess | Kiniksa Pharmaceuticals | 58 | |
| John Paolini | Kiniksa Pharmaceuticals | 59 | |
| Emily Hill | Replimune Group | 44 | |
| Raj MBA | Rocket Pharmaceuticals | 50 | |
| Lauren MBA | Day One Biopharmaceuticals | 48 | |
| Paul Cocja | Phathom Pharmaceuticals | N/A | |
| MD JD | Rocket Pharmaceuticals | N/A | |
| Jeffrey Jasper | Terns Pharmaceuticals | N/A | |
| Emil MD | Terns Pharmaceuticals | 44 | |
| Pamela Danagher | Terns Pharmaceuticals | N/A | |
| Elvia Cowan | Vaxcyte | 51 | |
| FACP MD | Protagonist Therapeutics | 65 | |
| Melissa Manno | Kiniksa Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -1.48 | ||||
| Return On Asset | -0.17 |
Uniqure NV Leadership Team
Elected by the shareholders, the Uniqure NV's board of directors comprises two types of representatives: Uniqure NV inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Uniqure. The board's role is to monitor Uniqure NV's management team and ensure that shareholders' interests are well served. Uniqure NV's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Uniqure NV's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Maria Cantor, Chief Officer | ||
| Carla Poulson, Interim Officer | ||
| Alexander Kuta, Ex Affairs | ||
| Ricardo Dolmetsch, Pres RD | ||
| Pierre Caloz, Chief Officer | ||
| Eileen Sawyer, Vice Affairs | ||
| Amin Abujoub, Chief Operations | ||
| Pr Katus, Chairman UniQureGermany | ||
| Matthew Kapusta, CEO Director | ||
| MBA Tugal, Business Director | ||
| Erin Boyer, Chief Officer | ||
| Richard Porter, Chief Officer | ||
| Walid MD, Chief Officer | ||
| Christian Klemt, Principal CFO | ||
| Matthew CPA, CEO Director | ||
| Jeannette JD, Chief Secretary | ||
| David Cerveny, Gen Officer |
Uniqure Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Uniqure NV a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.48 | ||||
| Return On Asset | -0.17 | ||||
| Operating Margin | (17.77) % | ||||
| Current Valuation | (85.91 M) | ||||
| Shares Outstanding | 48.74 M | ||||
| Shares Owned By Insiders | 9.23 % | ||||
| Shares Owned By Institutions | 81.95 % | ||||
| Number Of Shares Shorted | 3.35 M | ||||
| Price To Earning | 2.51 X | ||||
| Price To Book | 5.05 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Uniqure NV is a strong investment it is important to analyze Uniqure NV's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Uniqure NV's future performance. For an informed investment choice regarding Uniqure Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Uniqure NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Uniqure Stock refer to our How to Trade Uniqure Stock guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Uniqure NV. If investors know Uniqure will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Uniqure NV listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.18) | Earnings Share (4.95) | Revenue Per Share 0.591 | Quarterly Revenue Growth 0.625 | Return On Assets (0.17) |
The market value of Uniqure NV is measured differently than its book value, which is the value of Uniqure that is recorded on the company's balance sheet. Investors also form their own opinion of Uniqure NV's value that differs from its market value or its book value, called intrinsic value, which is Uniqure NV's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Uniqure NV's market value can be influenced by many factors that don't directly affect Uniqure NV's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Uniqure NV's value and its price as these two are different measures arrived at by different means. Investors typically determine if Uniqure NV is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Uniqure NV's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.